...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Experimental Hematology Oncology >Emerging therapies in advanced hepatocellular carcinoma
【24h】

Emerging therapies in advanced hepatocellular carcinoma

机译：高级肝细胞癌的新出现疗法

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Prognosis is very poor for advanced HCC patients partially due to lack of effective systemic treatment. Sorafenib was the only approved agent for advanced HCC since 2007 until recent breakthroughs. In this article, we will review the newer approved and promising agents in the treatment of advanced HCC in the first line setting and beyond progression. The Food and Drug Administration approved sorafenib as it demonstrated 3?months overall survival benefit compared to placebo in the first line setting over 10?years ago. Multiple single agent and combination therapies have been studied but failed to show benefit. Chemotherapy has limited role in patients with advanced HCC given poor hepatic reserve due to underlying cirrhosis. A new era of treatment for advanced HCC arrived recently with exciting data presented for lenvatinib, regorafenib, cabozantinib, nivolumab, ramucirumab and several other promising clinical trials. Advanced HCC patients are difficult to treat with poor outcomes. After initial approval of sorafenib in 2007, we recently have multiple new agents that showed benefit and promising activity, and are set to change the landscape of HCC treatment.
机译：由于缺乏有效的全身治疗，预后对于晚期HCC患者的预后非常差。 Sorafenib是自2007年以来的唯一批准的HCC批准的代理，直到最近的突破。在本文中，我们将审查较新的批准和有前途的代理，以便在第一线设置和超越进展中处理先进的HCC。食品和药物管理局批准了Sorafenib，因为它展示了3个月的3个月，而在10年前的第一行设置中与安慰剂相比，整体生存效益。研究了多种单一代理和组合疗法，但未能显示受益。化疗在患有晚期肝脏储备患者的患者中具有有限的作用，由于肝硬化潜水。最近举行的高级HCC治疗时代最近抵达Lenvatinib，Regorafenib，Cabozantinib，Nivolumab，Ramucirumab和其他一些有前途的临床试验。高级HCC患者难以治疗差的结果。在2007年初步批准Sorafenib后，我们最近有多种新的代理商，显示了福利和有希望的活动，并设定为改变HCC治疗的景观。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号